Optiscan Imaging Enters Collaboration Agreement with US Firm for Applications for Imaging Contrast Agent, Shares Jump 9%

MT Newswires Live

Jun 23

Optiscan Imaging (ASX:OIL) entered into an exclusive collaboration agreement with Long Grove Pharmaceuticals to develop new intended applications for Long Grove's intravenous drug, fluorescein sodium, or AK-FLOUR, according to a Monday Australian bourse filing.

AK-FLOUR is a contrast agent specifically used with Optiscan's current generation of fluorescence-based endomicroscopic imaging devices for surgical applications. The firms will develop new intended uses for the intravenous fluorescein sodium contrast agent.

AK-FLOUR will be used exclusively in US clinical studies and trials with Optiscan's InVue device in a range of clinical applications, starting with breast surgery. Data from the collaboration studies will be used to support Optiscan's US Food and Drug Administration regulatory submissions for its InVue surgical device.

Its shares jumped 9% in recent trading on Monday.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2545334450"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2545334450\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2545334450?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-06-23 09:59","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2545334450","market":"sh","top_or_hot":-1,"title":"Optiscan Imaging Enters Collaboration Agreement with US Firm for Applications for Imaging Contrast Agent, Shares Jump 9%","media":"MT Newswires Live","content":"<html><body><p> <a href=\"https://laohu8.com/S/OILN.AU\">Optiscan Imaging</a> (ASX:OIL) entered into an exclusive collaboration agreement with Long Grove Pharmaceuticals to develop new intended applications for Long Grove's intravenous drug, fluorescein sodium, or AK-FLOUR, according to a Monday Australian bourse filing.</p><p>AK-FLOUR is a contrast agent specifically used with Optiscan's current generation of fluorescence-based endomicroscopic imaging devices for surgical applications. The firms will develop new intended uses for the intravenous fluorescein sodium contrast agent.</p><p>AK-FLOUR will be used exclusively in US clinical studies and trials with Optiscan's InVue device in a range of clinical applications, starting with breast surgery. Data from the collaboration studies will be used to support Optiscan's US Food and Drug Administration regulatory submissions for its InVue surgical device.</p><p>Its shares jumped 9% in recent trading on Monday.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Optiscan Imaging Enters Collaboration Agreement with US Firm for Applications for Imaging Contrast Agent, Shares Jump 9%</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nOptiscan Imaging Enters Collaboration Agreement with US Firm for Applications for Imaging Contrast Agent, Shares Jump 9%\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2025-06-23 09:59</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> <a href=\"https://laohu8.com/S/OILN.AU\">Optiscan Imaging</a> (ASX:OIL) entered into an exclusive collaboration agreement with Long Grove Pharmaceuticals to develop new intended applications for Long Grove's intravenous drug, fluorescein sodium, or AK-FLOUR, according to a Monday Australian bourse filing.</p><p>AK-FLOUR is a contrast agent specifically used with Optiscan's current generation of fluorescence-based endomicroscopic imaging devices for surgical applications. The firms will develop new intended uses for the intravenous fluorescein sodium contrast agent.</p><p>AK-FLOUR will be used exclusively in US clinical studies and trials with Optiscan's InVue device in a range of clinical applications, starting with breast surgery. Data from the collaboration studies will be used to support Optiscan's US Food and Drug Administration regulatory submissions for its InVue surgical device.</p><p>Its shares jumped 9% in recent trading on Monday.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK7007","symbol_name":"医疗保健设备","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2545334450","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2545334450","pubTimestamp":1750643944,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Optiscan Imaging  entered into an exclusive collaboration agreement with Long Grove Pharmaceuticals to develop new intended applications for Long Grove's intravenous drug, fluorescein sodium, or AK-FLOUR, according to a Monday Australian bourse filing.AK-FLOUR is a contrast agent specifically used with Optiscan's current generation of fluorescence-based endomicroscopic imaging devices for surgical applications. The firms will develop new intended uses for the intravenous fluorescein sodium contrast agent.AK-FLOUR will be used exclusively in US clinical studies and trials with Optiscan's InVue device in a range of clinical applications, starting with breast surgery. Data from the collaboration studies will be used to support Optiscan's US Food and Drug Administration regulatory submissions for its InVue surgical device.Its shares jumped 9% in recent trading on Monday.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK7007":"医疗保健设备","OIL.AU":"OPTISCAN IMAGING LIMITED"},"translate_title":"Optiscan Imaging与美国公司就成像造影剂应用达成合作协议，股价上涨9%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"OIL.AU":0.9},"content_text":"Optiscan Imaging (ASX:OIL) entered into an exclusive collaboration agreement with Long Grove Pharmaceuticals to develop new intended applications for Long Grove's intravenous drug, fluorescein sodium, or AK-FLOUR, according to a Monday Australian bourse filing.AK-FLOUR is a contrast agent specifically used with Optiscan's current generation of fluorescence-based endomicroscopic imaging devices for surgical applications. The firms will develop new intended uses for the intravenous fluorescein sodium contrast agent.AK-FLOUR will be used exclusively in US clinical studies and trials with Optiscan's InVue device in a range of clinical applications, starting with breast surgery. Data from the collaboration studies will be used to support Optiscan's US Food and Drug Administration regulatory submissions for its InVue surgical device.Its shares jumped 9% in recent trading on Monday.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}